Brock L. Schweitzer

Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial

John H. Strickler, Tyler Zemla, Fang‐Shu Ou et al. · Annals of Oncology · 2019 · 92 citations · Full text

Initial Results, Gastrointestinal Oncology, Medicine +8

BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study

Niharika B. Mettu, Erin Twohy, Fang‐Shu Ou et al. · Annals of Oncology · 2019 · 72 citations

Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients

Brian Z. Ring, David R. Hout, Stephan W. Morris et al. · BMC Cancer · 2016 · 70 citations · Full text

Regulation of the Interleukin-7 Receptor α Promoter by the Ets Transcription Factors PU.1 and GA-binding Protein in Developing B Cells

Rodney P. DeKoter, Brock L. Schweitzer, Meghana B. Kamath et al. · Journal of Biological Chemistry · 2007 · 63 citations · Full text

Reduction in PU.1 activity results in a block to B-cell development, abnormal myeloid proliferation, and neonatal lethality

Isaac B. Houston, Meghana B. Kamath, Brock L. Schweitzer et al. · Experimental Hematology · 2007 · 52 citations · Full text

Lymphocyte Development, Apoptosis, Immunology +16